17 May 2022

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Notice of AGM

Ondine Biomedical Inc. (AIM: OBI) announces that its annual general meeting ("AGM") will be held virtually at 8:00a.m. (Pacific time) on 7 June 2022.

A copy of the notice of AGM is available on the Company's website at https://ondinebio.com/.

This year, out of an abundance of caution and to continue to deal with the unprecedented health impact of coronavirus disease ("COVID-19") and mitigate risks to the health and safety of communities, shareholders, employees and other stakeholders, the Company will hold its AGM in a virtual only format, which will be conducted via live audio webcast.

A virtual presentation and Q&A session for investors and analysts will be held at 9.00am (Pacific time) on the day of results. The presentation and webcast details will be made available on the Company's website at https://ondinebio.com/investors/reports-documentation/

Please register to attend the investor presentation (full link below).

https://www.lsegissuerservices.com/spark/ONDINEBIOMEDICALINC/events/5d389d61-eb74-4617-9eb0-026060322915

**ENDS**

About Ondine Biomedical Inc.

Ondine Biomedical Inc. (AIM: OBI) is a Canadian headquartered, medical device company led by founder and CEO, Carolyn Cross. Ondine has developed a patented, painless, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - including multidrug-resistant strains. Photodisinfection is a targeted antimicrobial which uses non-thermal light to activate a photosensitive agent. In a few minutes, this light-based therapy destroys the pathogens' cell membranes and surface proteins through an oxidative burst without any impact on human tissue. 

Ondine has a pipeline of products, based on its patent protected photodisinfection platform, in various stages of development. Products include treatment of chronic rhinosinusitis, decolonisation of infections in burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce viral titres and transmission of respiratory viruses (e.g., SARS-CoV-2, influenza, RSV, etc.). Ondine's technology is approved in a number of jurisdictions and has been awarded the CE mark, as well as Qualified Infectious Disease Product and Fast Track status in the U.S. by the FDA.

For more information, please visit:  www.ondinebio.com or contact: